352 related articles for article (PubMed ID: 27530271)
1. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
[TBL] [Abstract][Full Text] [Related]
2. Current progress in NK cell biology and NK cell-based cancer immunotherapy.
Tarazona R; Lopez-Sejas N; Guerrero B; Hassouneh F; Valhondo I; Pera A; Sanchez-Correa B; Pastor N; Duran E; Alonso C; Solana R
Cancer Immunol Immunother; 2020 May; 69(5):879-899. PubMed ID: 32130453
[TBL] [Abstract][Full Text] [Related]
3. New directions in natural killer cell-based immunotherapy of human cancer.
Farag SS; Fehniger TA; Becknell B; Blaser BW; Caligiuri MA
Expert Opin Biol Ther; 2003 Apr; 3(2):237-50. PubMed ID: 12662139
[TBL] [Abstract][Full Text] [Related]
4. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
5. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B; Campos C; Pera A; Bergua JM; Arcos MJ; Bañas H; Casado JG; Morgado S; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2016 Apr; 65(4):453-63. PubMed ID: 26059279
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
8. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
11. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
12. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
13.
Elsner L; Dressel R
Methods Enzymol; 2020; 631():497-512. PubMed ID: 31948566
[TBL] [Abstract][Full Text] [Related]
14. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
15. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
16. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell therapies.
Vivier E; Rebuffet L; Narni-Mancinelli E; Cornen S; Igarashi RY; Fantin VR
Nature; 2024 Feb; 626(8000):727-736. PubMed ID: 38383621
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
Front Immunol; 2020; 11():2156. PubMed ID: 33013909
[TBL] [Abstract][Full Text] [Related]
19. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
[TBL] [Abstract][Full Text] [Related]
20. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
